New Brain PET Scanner Shows Promise for Earlier and Less Expensive Diagnosis of Parkinson’s
A new brain scanner, which is 10 times less expensive and much smaller than current models, has the potential to…
Articles by Patricia Inácio, PhD
Neurodegenerative Disease Mechanisms May Begin Soon After Birth, Mouse Study Suggests
The mechanisms that lead to progressive degenerative diseases like Parkinson’s in adulthood begin much earlier than previously thought, a mouse study…
Using Artificial Intelligence to Analyze Brain Cells May Revolutionize Research
Computers may be taught to identify features in nerve cells that have not been stained or undergone other damaging treatments for…
#AAN2018 – Neural Stem Cell-Based Therapy is Safe, May Benefit Patients, Early Test Results Suggest
Human neural stem cells show promise as therapy for Parkinson’s disease, according to six-month interim results of Phase 1 trial.
NIH awards $228,325 to Tech Startup to Develop MRI Device for Improved Diagnosis
A startup developing a device for more affordable and efficient magnetic resonance imaging (MRI) scans was recently awarded a Small Business…
2 Markers of Parkinson’s Progression May Help Trials in Newly Diagnosed Patients, Study Says
Clinical trials in patients with early stage Parkinson’s may benefit from assessing markers of disease progression — namely, changes in…
New Scanner Worn as Helmet Allows Brain Imaging in Parkinson’s Patients
A new brain scanner that can be worn as a helmet could potentially revolutionize the world of human brain imaging,…
Deep Brain Stimulation for Parkinson’s Disease: The Past and What the Future Holds
Despite being used for the past 30 years to treat chronic neurological diseases, including Parkinson’s disease (PD),…
Gocovri Significantly Improves Dyskinesia and ‘Off’ Time in Parkinson’s, New Analysis Confirms
Parkinson’s disease patients treated with Gocovri (amantadine) experienced a 41 percent decrease in levodopa-induced dyskinesia compared to 14 percent of…
Lundbeck Acquires Rights to Develop Foliglurax Therapy Candidate to Treat Parkinson’s
Lundbeck will acquire the biopharmaceutical Prexton Therapeutics, obtaining the development and commercialization rights to foliglurax (PTX002331), an investigational therapy currently…